Login to Your Account



Clovis shares dip as investors mull ESMO data

By Michael Fitzhugh
Staff Writer

Friday, October 7, 2016

Clovis Oncology Inc. shares fell 17.8 percent on Friday as investors wrestled with the competitive implications of data submitted in rucaparib's NDA and presented at the European Society for Medical Oncology congress in Copenhagen.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription